Fält I C, Schweda E K, Klee S, Singh M, Floderus E, Timmis K N, Lindberg A A
Department of Immunology, Microbiology, Pathology, and Infectious Diseases, Karolinska Institute, Huddinge, Sweden.
J Bacteriol. 1995 Sep;177(18):5310-5. doi: 10.1128/jb.177.18.5310-5315.1995.
The potential utility of Shigella flexneri aroD vaccine candidates for the development of bi- or multivalent vaccines has been explored by the introduction of the genetic determinants rfp and rfb for heterologous O antigen polysaccharide from Shigella dysenteriae serotype 1. The serotype Y vaccine strain SFL124 expressed the heterologous antigen qualitatively and quantitatively well, qualitatively in the sense of the O antigen polysaccharide being correctly linked to the S. flexneri lipopolysaccharide R3 core oligosaccharide and quantitatively in the sense that typical yields were obtained, with ratios of homologous to heterologous O antigen being 4:1 for one construct and 1:1 for another. Moreover, both polysaccharide chains were shown to be linked to position O-4 of the subterminal D-glucose residue of the R3 core. In contrast to the hybrid serotype Y SFL124 derivatives, analogous derivatives of serotype 2a vaccine strain SFL1070 did not elaborate a complete heterologous O antigen. Such derivatives, and analogous derivatives of rough, O antigen-negative mutants of SFL1070, formed instead a hybrid lipopolysaccharide molecule consisting of the S. flexneri lipid A R3 core with a single repeat unit of the S. dysenteriae type 1 O antigen. Introduction of the determinants for the S. dysenteriae type 1 O antigen into a second serotype 2a strain and into strains representing other serotypes of S. flexneri, revealed the following for the expression of the heterologous O antigen: serotypes 1a, 1b, 2a, and 5a did not produce the heterologous O antigen, whereas serotypes 2b, 3a, 3b, 4a, 4b, 5b, and X did.
通过引入来自痢疾志贺氏菌1型的异源O抗原多糖的遗传决定因子rfp和rfb,探索了弗氏志贺氏菌aroD候选疫苗在开发二价或多价疫苗方面的潜在效用。血清型Y疫苗株SFL124在定性和定量方面均能很好地表达异源抗原,定性方面是指O抗原多糖与弗氏志贺氏菌脂多糖R3核心寡糖正确连接,定量方面是指获得了典型产量,一种构建体中同源O抗原与异源O抗原的比例为4:1,另一种构建体中为1:1。此外,两条多糖链均显示与R3核心亚末端D-葡萄糖残基的O-4位相连。与杂交血清型Y SFL124衍生物不同,血清型2a疫苗株SFL1070的类似衍生物未形成完整的异源O抗原。此类衍生物以及SFL1070粗糙、O抗原阴性突变体的类似衍生物,反而形成了一种杂交脂多糖分子,该分子由弗氏志贺氏菌脂质A R3核心和痢疾志贺氏菌1型O抗原的单个重复单元组成。将痢疾志贺氏菌1型O抗原的决定因子引入第二株血清型2a菌株以及代表弗氏志贺氏菌其他血清型的菌株中,关于异源O抗原的表达情况如下:血清型1a、1b、2a和5a不产生异源O抗原,而血清型2b、3a、3b、4a、4b、5b和X则产生。